- Home
- ULCC vs QURE Comparison
ULCC vs QURE Comparison
Compare ULCC & QURE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ULCC
- QURE
- Stock Information
- Founded
- ULCC 1994
- QURE 1998
- Country
- ULCC United States
- QURE Netherlands
- Employees
- ULCC N/A
- QURE N/A
- Industry
- ULCC Air Freight/Delivery Services
- QURE Biotechnology: Pharmaceutical Preparations
- Sector
- ULCC Consumer Discretionary
- QURE Health Care
- Exchange
- ULCC Nasdaq
- QURE Nasdaq
- Market Cap
- ULCC 719.5M
- QURE 725.4M
- IPO Year
- ULCC 2021
- QURE 2007
- Fundamental
- Price
- ULCC $4.01
- QURE $14.49
- Analyst Decision
- ULCC Hold
- QURE Strong Buy
- Analyst Count
- ULCC 11
- QURE 10
- Target Price
- ULCC $5.56
- QURE $37.20
- AVG Volume (30 Days)
- ULCC 3.4M
- QURE 2.1M
- Earning Date
- ULCC 05-01-2025
- QURE 05-09-2025
- Dividend Yield
- ULCC N/A
- QURE N/A
- EPS Growth
- ULCC N/A
- QURE N/A
- EPS
- ULCC 0.30
- QURE N/A
- Revenue
- ULCC $3,822,000,000.00
- QURE $20,201,000.00
- Revenue This Year
- ULCC $4.58
- QURE $60.54
- Revenue Next Year
- ULCC $13.93
- QURE $183.28
- P/E Ratio
- ULCC $13.38
- QURE N/A
- Revenue Growth
- ULCC 5.99
- QURE 6.30
- 52 Week Low
- ULCC $2.79
- QURE $3.73
- 52 Week High
- ULCC $10.26
- QURE $19.18
- Technical
- Relative Strength Index (RSI)
- ULCC 52.19
- QURE 53.84
- Support Level
- ULCC $3.60
- QURE $14.06
- Resistance Level
- ULCC $4.38
- QURE $16.20
- Average True Range (ATR)
- ULCC 0.24
- QURE 0.95
- MACD
- ULCC 0.04
- QURE -0.02
- Stochastic Oscillator
- ULCC 47.13
- QURE 54.02
About ULCC Frontier Group Holdings Inc.
Frontier Group Holdings Inc is an ultra-low-cost carrier whose business is focused on Low Fares Done Right. The company owns a fleet of 120 Airbus single-aisle aircraft, consisting of 13 A320ceos, 82 A320neos, 21 A321ceos and 4 A321neos. The use of these aircraft, their seating configuration, weight-saving tactics, and baggage process have all contributed to the ability to continue to be the fuel-efficient of all the U.S. The Company is managed as a single business unit that provides air transportation for passengers. Majority of revenue is from Domestic flight follow by International.
About QURE uniQure N.V.
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases.